Suppr超能文献

用于牙科抗菌光动力疗法的粘性亚甲蓝制剂

Viscous methylene blue formulation for antimicrobial photodynamic therapy in dentistry.

作者信息

Monteiro Carolina Montovam, Gonçalves José Marcelo Lacerda Alves, Machado Gabriela Benedito, Chiarelli-Neto Orlando, Prates Renato Araújo, Frochot Céline, Pavani Christiane

机构信息

Biophotonics Medicine Postgraduate Program, Universidade Nove de Julho, Rua Vergueiro 235-249, São Paulo, SP, 01504-001, Brazil.

Centro Universitário do Espírito Santo, Colatina, ES, Brazil.

出版信息

Sci Rep. 2025 May 6;15(1):15751. doi: 10.1038/s41598-025-98568-x.

Abstract

Antimicrobial photodynamic therapy (aPDT) is a promising strategy to combat resistant microbial strains. However, despite its high in vitro efficacy, clinical outcomes often fall short, largely due to insufficient retention of the photosensitizer (PS) at the target site. Factors such as salivary flow and PS aggregation significantly hinder the effectiveness of aPDT. This study presents the development of a high-viscosity methylene blue (MB) formulation tailored for dental aPDT applications. The increased viscosity aims to enhance PS retention at the treatment site, while carefully selected components address MB aggregation, ultimately improving the clinical efficacy of the therapy. Key formulation strategies included the incorporation of a surfactant, anionic polymers, an acidic pH, and reduced MB concentrations to effectively mitigate aggregation. Stability testing demonstrated that the formulation preserved its organoleptic properties, pH, and MB content over 1 year. Although the formulation exhibited lower MB uptake in Candida albicans biofilms compared to aqueous MB, this did not compromise its antimicrobial activity. In vitro aPDT assays showed comparable efficacy between MB in water and the high-viscosity formulation. These findings highlight the potential of the developed viscous MB formulation to enhance the practicality and clinical success of aPDT in dentistry, without compromising its therapeutic effectiveness.

摘要

抗菌光动力疗法(aPDT)是对抗耐药微生物菌株的一种有前景的策略。然而,尽管其在体外具有高效性,但临床结果往往不尽人意,这主要是由于光敏剂(PS)在靶部位的滞留不足。唾液流动和PS聚集等因素显著阻碍了aPDT的有效性。本研究介绍了一种专为牙科aPDT应用量身定制的高粘度亚甲蓝(MB)制剂的研发。粘度增加旨在提高PS在治疗部位的滞留,同时精心选择的成分解决MB聚集问题,最终提高该疗法的临床疗效。关键的制剂策略包括加入表面活性剂、阴离子聚合物、酸性pH值以及降低MB浓度以有效减轻聚集。稳定性测试表明,该制剂在1年多的时间里保持了其感官特性、pH值和MB含量。尽管与水性MB相比,该制剂在白色念珠菌生物膜中的MB摄取较低,但这并未损害其抗菌活性。体外aPDT试验表明,水中的MB与高粘度制剂之间的疗效相当。这些发现突出了所开发的粘性MB制剂在不损害其治疗效果的情况下,增强aPDT在牙科的实用性和临床成功率的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac8/12055992/9de3530bf293/41598_2025_98568_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验